476.5000 1.55 (0.33%)
NSE Sep 19, 2025 15:31 PM
Volume: 84,736
 

476.50
0.33%
ICICI Securities Limited
We recently hosted Akums’ management for a roadshow. Akums has been able to maintain its CDMO and overall EBITDA margin at 15.5%/12.0% despite its sub-par revenue growth in 9MFY25. Further efforts towards curbing losses in API division and new export order (starting CY27) could drive operating leverage and boost margins in coming years.
Akums Drugs & Pharmaceuticals Ltd. is trading above its 30 day SMA of 473.0
More from Akums Drugs & Pharmaceuticals Ltd.
Recommended